


## Trazodone-d<sub>6</sub> hydrochloride

<b>Cat. No.:</b>	HY-B0478AS	
<b>CAS No.:</b>	1181578-71-1	
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>17</sub> D <sub>6</sub> Cl <sub>2</sub> N <sub>5</sub> O	
<b>Molecular Weight:</b>	414.36	
<b>Target:</b>	5-HT Receptor; Isotope-Labeled Compounds	
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Others	
<b>Storage:</b>	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 16.67 mg/mL (40.23 mM; Need ultrasonic)  
 H<sub>2</sub>O : 16.67 mg/mL (40.23 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.4134 mL	12.0668 mL	24.1336 mL
	5 mM	0.4827 mL	2.4134 mL	4.8267 mL
	10 mM	0.2413 mL	1.2067 mL	2.4134 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Trazodone-d<sub>6</sub> (hydrochloride) is the deuterium labeled Trazodone hydrochloride[1].

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA